STOCK TITAN

AMGEN TO PRESENT AT CITI'S 2024 GLOBAL HEALTHCARE CONFERENCE

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Amgen (NASDAQ:AMGN) has announced its participation in Citi's 2024 Global Healthcare Conference on Thursday, Dec. 5, 2024, at 9:30 a.m. ET. The company will be represented by three executive leaders: Peter Griffith (EVP and CFO), Jay Bradner (EVP of R&D and CSO), and Susan Sweeney (EVP of Obesity and Related Conditions), who will engage in a fireside chat.

The presentation will be webcast live and made accessible to investors, media, and the public through Amgen's website. The webcast recording will remain available for replay on www.amgen.com under the Investors section for at least 90 days following the event.

Amgen (NASDAQ:AMGN) ha annunciato la sua partecipazione alla Conferenza Sanitaria Globale 2024 di Citi giovedì 5 dicembre 2024, alle 9:30 ET. L'azienda sarà rappresentata da tre leader esecutivi: Peter Griffith (EVP e CFO), Jay Bradner (EVP di Ricerca e Sviluppo e CSO) e Susan Sweeney (EVP di Obesità e Condizioni Correlate), che parteciperanno a una chiacchierata informale.

La presentazione sarà trasmessa in diretta e sarà accessibile a investitori, media e pubblico attraverso il sito web di Amgen. La registrazione della trasmissione rimarrà disponibile per la visione su www.amgen.com nella sezione Investitori per almeno 90 giorni dopo l'evento.

Amgen (NASDAQ:AMGN) ha anunciado su participación en la Conferencia Global de Salud 2024 de Citi el jueves 5 de diciembre de 2024, a las 9:30 a.m. ET. La compañía estará representada por tres líderes ejecutivos: Peter Griffith (EVP y CFO), Jay Bradner (EVP de I+D y CSO), y Susan Sweeney (EVP de Obesidad y Condiciones Relacionadas), quienes participarán en una charla informal.

La presentación se transmitirá en vivo y estará disponible para inversores, medios y el público a través del sitio web de Amgen. La grabación de la transmisión estará disponible para volver a ver en www.amgen.com en la sección de Inversores durante al menos 90 días después del evento.

암젠 (NASDAQ:AMGN)은 2024년 12월 5일 목요일 오전 9시 30분 ET에 씨티의 2024 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사는 피터 그리피스(EVP 및 CFO), 제이 브래드너(EVP 연구개발 및 CSO), 수잔 스위니(EVP 비만 및 관련 질환) 등 세 명의 임원들이 대담에 참여할 예정입니다.

발표는 라이브 웹캐스트로 진행되며, 암젠 웹사이트를 통해 투자자, 언론 및 일반 대중에게 공개됩니다. 웹캐스트 녹화는 이벤트 후 최소 90일 동안 www.amgen.com의 투자자 섹션에서 다시 볼 수 있습니다.

Amgen (NASDAQ:AMGN) a annoncé sa participation à la Conférence Mondiale sur la Santé 2024 de Citi le jeudi 5 décembre 2024, à 9h30 ET. L'entreprise sera représentée par trois dirigeants : Peter Griffith (EVP et CFO), Jay Bradner (EVP de R&D et CSO), et Susan Sweeney (EVP de l'Obésité et Conditions Associées), qui participeront à une discussion informelle.

La présentation sera diffusée en direct et accessible aux investisseurs, aux médias et au public via le site web d'Amgen. L'enregistrement de la diffusion restera disponible en replay sur www.amgen.com dans la section Investisseurs pendant au moins 90 jours après l'événement.

Amgen (NASDAQ:AMGN) hat seine Teilnahme an der Citi Global Healthcare Conference 2024 am Donnerstag, den 5. Dezember 2024, um 9:30 Uhr ET bekannt gegeben. Das Unternehmen wird von drei Führungskräften vertreten: Peter Griffith (EVP und CFO), Jay Bradner (EVP für Forschung und Entwicklung und CSO) und Susan Sweeney (EVP für Adipositas und verwandte Erkrankungen), die in einem informellen Gespräch teilnehmen werden.

Die Präsentation wird live gestreamt und für Investoren, Medien und die Öffentlichkeit über die Website von Amgen zugänglich gemacht. Die Aufzeichnung des Streams wird auf www.amgen.com im Bereich Investoren für mindestens 90 Tage nach der Veranstaltung verfügbar sein.

Positive
  • None.
Negative
  • None.

THOUSAND OAKS, Calif., Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday, Dec. 5, 2024. Peter Griffith, executive vice president and chief financial officer at Amgen, Jay Bradner, executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney, executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. 

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. 

About Amgen 
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.  

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. 

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. 

For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn, Instagram, TikTok, YouTube and Threads

Amgen Forward-Looking Statements
This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all.

CONTACT: Amgen, Thousand Oaks 
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)   

Amgen Logo. (PRNewsFoto/Amgen) (PRNewsFoto/)

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html

SOURCE Amgen

FAQ

When is Amgen (AMGN) presenting at Citi's 2024 Global Healthcare Conference?

Amgen is presenting at Citi's 2024 Global Healthcare Conference on Thursday, December 5, 2024, at 9:30 a.m. ET.

Which Amgen executives are speaking at Citi's 2024 Healthcare Conference?

Peter Griffith (EVP & CFO), Jay Bradner (EVP of R&D & CSO), and Susan Sweeney (EVP of Obesity and Related Conditions) will participate in a fireside chat.

How can investors watch Amgen's (AMGN) presentation at Citi's 2024 Healthcare Conference?

Investors can watch the presentation via webcast on Amgen's website (www.amgen.com) under the Investors section.

How long will Amgen's (AMGN) Citi Conference presentation be available for replay?

The webcast will be archived and available for replay for at least 90 days after the event.

Amgen Inc

NASDAQ:AMGN

AMGN Rankings

AMGN Latest News

AMGN Stock Data

143.27B
536.09M
0.21%
81.11%
1.82%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS